BRAF V600突变的临床试验
总计1653个结果
-
Weill Medical College of Cornell University完全的
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Istituto Oncologico di Bari完全的
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia Therapeutics Limited 和其他合作者招聘中
-
Cancer Institute and Hospital, Chinese Academy...尚未招聘难治性淋巴瘤 | DLBCL | MYD88基因突变 | 复发 | CD79A基因突变 | CD79B基因突变
-
Universitaire Ziekenhuizen KU Leuven完全的
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical Center, Cincinnati招聘中
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Merck Sharp & Dohme LLC主动,不招人
-
Boehringer Ingelheim主动,不招人
-
Affiliated Hospital to Academy of Military Medical...招聘中
-
The University of Hong Kong未知
-
AZ-VUB未知
-
University of AberdeenKellogg Company完全的
-
Okayama UniversityMerck Sharp & Dohme LLC招聘中乳腺癌 | 乳腺肿瘤 | 三阴性乳腺癌 | 三阴性乳腺肿瘤 | BRCA1突变 | BRCA2突变 | BRCA突变 | BRCA 相关性乳腺癌日本
-
Korean Cancer Study Group未知
-
University of Chicago招聘中
-
Massachusetts General HospitalAgios Pharmaceuticals, Inc.完全的
-
NYU Langone Health撤销乳腺癌 | BRCA1突变 | BRCA2突变美国
-
Sumitomo Pharma America, Inc.完全的
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)主动,不招人BRCA1基因突变 | BRCA2基因突变 | 转移性恶性肿瘤 | 晚期恶性肿瘤 | 复发性恶性肿瘤 | 难治性恶性肿瘤 | PALB2基因突变 | ATM基因突变美国
-
Boehringer Ingelheim主动,不招人
-
Shandong UniversityFudan University; Chinese Nutrition Society完全的
-
University Health Network, TorontoBayer; AstraZeneca; Amgen; Applied Health Research Centre; Takeda Canada, Inc.; Programs for Assessment...招聘中癌症 | 多发性恶性肿瘤 | 恶性实体瘤 | 癌症,治疗相关 | 分子序列变异 | 遗传改变 | 基因融合 | 受体酪氨酸激酶基因突变 | RTK家族基因突变 | Ras(Kras 或 Nras)基因突变加拿大
-
Royal Marsden NHS Foundation Trust完全的
-
Southwest Oncology GroupNational Cancer Institute (NCI)完全的
-
Liberating Technologies, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Worcester...完全的
-
Istituto Clinico HumanitasCelgene未知
-
Georgetown UniversityImmune System Key Ltd招聘中
-
University of California, San Francisco终止ALK融合蛋白表达 | III 期皮肤黑色素瘤 | IIIA 期皮肤黑色素瘤 | IIIB 期皮肤黑色素瘤 | IIIC 期皮肤黑色素瘤 | IV 期皮肤黑色素瘤 | ROS1融合阳性 | BRAF 等位基因 | 侵袭性皮肤黑色素瘤 | MET融合基因阳性 | NRAS wt 等位基因 | NTRK1融合阳性 | NTRK2融合阳性 | NTRK3融合阳性 | RET融合阳性美国
-
Centre Hospitalier Universitaire de Besancon完全的
-
Ruijin Hospital招聘中
-
Blueprint Medicines Corporation完全的全身肥大细胞激活 | KIT D816V突变美国, 法国, 英国, 意大利, 德国, 比利时, 西班牙, 瑞士
-
Hubei Biological Medicine Industrial Technology...未知
-
Severance HospitalSamsung Medical Center; Asan Medical Center; Kyungpook National University Chilgok Hospital招聘中
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)主动,不招人
-
AstraZeneca完全的
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.尚未招聘BRCA1突变 | BRCA2突变 | PALB2基因突变 | 激素受体阳性 HER-2 阴性乳腺癌 | 晚期或转移性乳腺癌德国
-
Hellenic Cooperative Oncology Group主动,不招人
-
City of Hope Medical CenterNational Cancer Institute (NCI)主动,不招人
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)未知乳腺癌 | brca1突变携带者 | brca2突变携带者美国
-
Calithera Biosciences, Inc完全的